Cell-based Assay Firm Odyssey Thera Raises $2.8M | GenomeWeb

NEW YORK (GenomeWeb News) – Biotech firm Odyssey Thera has raised $2.8 million and initiated a research service contract with Merck, it announced on Thursday.

The financing, consisting of new funds and debt conversion, will go toward the development and expanded commercialization of the San Ramon, Calif.-based company's technologies and products.

Participants in the round include Merck, HBM Partners, Burrill & Co., and Lonza.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.